To Evaluate the Efficacy and Safety of LIZTOX in Subjects with Benign Masseteric Hypertrophy

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

188

Participants

Timeline

Start Date

July 25, 2023

Primary Completion Date

March 7, 2024

Study Completion Date

May 30, 2025

Conditions

Benign Masseteric Hypertrophy

Interventions

DRUG

Botulinum toxin type A

Botulinum toxin type A(HU-014) will be administered intramuscularly to the bilateral masseter muscles on Visit 2.

DRUG

normal Saline

Normal Saline will be administered intramuscularly to the bilateral masseter muscles on Visit 2.

Trial Locations (1)

Chung-Ang University Hospital, Dongjak